RUTHERFORD, N.J., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Panna Sharma, president and CEO of Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, provides insight and commentary on its expanding relationship with Roche Servicios, S.A., an affiliate of Swiss drug maker Roche, in this pre-recorded video interview. Click here to view:
Some key highlights covered in the interview with Mr. Sharma include:
- Strengthening of relationship with Roche Servicios
- Forecast for rapid adoption of genetic testing for cancer over the next five years
- Depth and strength of CGIX product portfolio in comparison with its peers
- Establishment of joint certification program with Roche designed to drive adoption of DNA-based cancer diagnostic tools at hundreds of hospitals in Central America and the Caribbean
- Expansion of CGIX test menu and enhancement of the Company's relationships outside the U.S.
- How personalized medicine is impacting lives and changing the economics of cancer care
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 email@example.comSource:Cancer Genetics